Halozyme (HALO) | Stock Overview & Key Data
Halozyme Performance Comparison
Stock Range
Today's Range
Low: $68.99
High: $70.70
on August 19, 2025
52 Week Range
Low: $42.01
High: $70.70
on November 18, 2024
on August 19, 2025
All-Time High: $70.70 on August 19, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$8.2B
EPS
4.37
P/E Ratio (TTM)
16.01
Forward P/E
14.46
P/B Ratio
24.74
PEG Ratio
0.19
Div. Yield
N/A
ROE
179.14%
Beta
1.173
Debt to Equity
462.23
Financial Highlights
Profitability
Gross Margin
85.77%
Operating Margin
62.15%
Profit Margin
47.28%
Returns and Earnings
Return on Assets (TTM)
21.21%
Return on Equity (TTM)
179.14%
EBITDA
$764.4M
Net Income (TTM)
$557.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$9.57
Quarterly Revenue Growth (YoY)
40.80%
Quarterly Earnings Growth (YoY)
77.10%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Halozyme HALO | 8.19B Mid-cap | 9.28% | 25.14% | 31.29% | 21.14% | 45.76% | 11.58% | 73.69% | 146.06% |
| Vertex VRTX | 100.71B Large-cap | 0.77% | -14.77% | -11.32% | -17.17% | -3.70% | -18.80% | 38.72% | 44.75% |
| Regeneron REGN | 61.52B Large-cap | 2.74% | 4.81% | -4.15% | -16.61% | -20.05% | -52.32% | -4.09% | -5.12% |
| BridgeBio Pharma BBIO | 9.39B Mid-cap | -0.37% | 6.56% | 45.18% | 34.78% | 73.44% | 93.24% | 366.70% | 65.29% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
| Madrigal MDGL | 8.46B Mid-cap | 5.72% | 14.69% | 30.56% | 10.45% | 20.96% | 50.17% | 441.75% | 255.92% |
Ownership & Short Interest
Insider Ownership
1.17%
Institutional Ownership
102.70%
Shares Short
10M
Short Ratio
6.61
Short % of Shares Outstanding
11.86%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Halozyme Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Halozyme would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is HALO's 52-week high and low?
- In the last 52 weeks, Halozyme reached a high of $70.70 (on August 19, 2025) and a low of $42.01 (on November 18, 2024).
- What is the market cap and P/E ratio for HALO?
- Curious about Halozyme's size and valuation? Its market capitalization stands at 8.19B. When it comes to valuation, the P/E ratio (trailing twelve months) is 16.01, and the forward P/E (looking ahead) is 14.46.
- Does HALO pay dividends? If so, what's the yield?
- As for dividends, Halozyme isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Halozyme's main competitors or similar companies to consider before investing?
When looking at Halozyme, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.71B Healthcare Biotechnology -18.80% 38.72% Regeneron
REGN61.52B Healthcare Biotechnology -52.32% -4.09% BridgeBio Pharma
BBIO9.39B Healthcare Biotechnology 93.24% 366.70% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% Madrigal
MDGL8.46B Healthcare Biotechnology 50.17% 441.75% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Halozyme Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Halozyme's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 179.14%, the Debt to Equity ratio from the most recent quarter is 462.23, and its Gross Profit Margin stands at 85.77%.
- What is the recent revenue and earnings growth for HALO?
- Looking at Halozyme's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 40.80%, and quarterly earnings saw a YoY growth of 77.10%.
- How much of HALO stock is held by insiders and institutions?
- Wondering who owns Halozyme stock? Company insiders (like executives and directors) hold about 1.17% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 102.70%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.